Fatoş ÖNEN, İsmail SARI, Tuba YÜCE İNEL, Ali KARAKAŞ

The effect of COVID-19 pandemic in a large series of patients with Takayasu arteritis

Background/aim: Patients with inflammatory rheumatic diseases faced several challenges during the COVID-19 pandemic. Uncertainties such as the lack of evidence regarding the use of immunosuppressive (IS) therapies and deferred patient care because of limited health resources affected negatively on many aspects of treatment decisions and routine follow-up of the patients. In this study, we aimed to investigate the prevalence and severity of SARS-CoV-2 infection, the impact of the pandemic on delays in routine clinical follow-up, changes in IS treatment, and COVID-19 vaccination status of patients with Takayasu arteritis (TAK). Materials and methods: The study was performed between July and September 2021. TAK patients who registered in our database were investigated with regards to the COVID-19 infection and vaccination status, delays in routine clinical visits, changes in their IS treatments, and flares during the pandemic. Physical examination, laboratory tests, and imaging of the patients were performed and ITAS2010 scores were calculated. Results: There were 56 adult TAK patients (87.5% female and median age 47 years). A total of 44 (78.6%) patients experienced a delay with routine follow-up visits to their physicians and about 20% of patients stopped their antirheumatic treatments without consulting their physicians. Compared to the pre-COVID-19 pandemic, 16 (28.5%) patients flared. In total group, 13 (23.2%) patients had a mild COVID-19 infection and about 90% of the patients had received the COVID-19 vaccine. Conclusion: Deferred patient care and disease flares are the most significant problems in TAK patients during the pandemic. The risk of TAK flares may outweigh the risk of COVID-19 infection.

PDF

___

1. Harapan H, Itoh N, Yufika A, Winardi W, Keam S et al. Coronavirus disease 2019 (COVID-19): A literature review. Journal of Infection and Public Health 2020; 13 (5): 667-673. doi: 10.1016/j.jiph.2020.03.019
2. Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Annals of the Rheumatic Disease 2020; 79 (7): 988-990. doi: 10.1136/ annrheumdis-2020-217948
3. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Disease 2020; 79 (7): 859- 866. doi: 10.1136/annrheumdis-2020-217871
4. Keser G, Aksu K, Direskeneli H. Takayasu arteritis: an update. Turkısh Journal of Medical Sciences 2018; 48 (4): 681-697. doi: 10.3906/sag-1804-136
5. Emmi G, Bettiol A, Mattioli I, Silvestri E, Di Scala G et al. SARSCoV-2 infection among patients with systemic autoimmune diseases. Autoimmunity Reviews 2020; 19 (7): 102575. doi: 10.1016/j.autrev.2020.102575
6. Tomelleri A, Sartorelli S, Campochiaro C, Baldissera EM, Dagna L. Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Annals of the Rheumatic Disease 2020; 79 (9): 1252-1253. doi: 10.1136/ annrheumdis-2020-217600
7. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis & Rheumatology 1990; 33 (8): 1129-1134. doi: 10.1002/art.1780330811
8. Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 2013; 52 (10): 1795-1801. doi: 10.1093/rheumatology/ket128
9. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS et al. Takayasu arteritis. Annals of Internal Medicine 1994; 120 (11): 919-929. doi: 10.7326/0003-4819-120-11-199406010-00004
10. Yek C, Warner S, Wiltz JL, Sun J, Adjei S et al. Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020 - October 2021. Morbidity and Mortality Weekly Report 2022; 71 (1): 19-25. doi: 10.15585/mmwr.mm7101a4
11. Comarmond C, Leclercq M, Leroux G, Marques C, Le Joncour A et al. Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’. Annals of the Rheumatic Disease 2020; annrheumdis-2020-219407. doi: 10.1136/ annrheumdis-2020-219407
12. Banerjee S, George M, Young K, Venkatachalam S, Gordon J et al. Effects of the COVID-19 Pandemic on Patients Living With Vasculitis. ACR Open Rheumatology 2021; 3 (1): 17-24. doi: 10.1002/acr2.11204
13. Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R et al. Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data? Arthritis & Rheumatology 2020; 72 (10): 1600-1606. doi: 10.1002/art.41388
14. Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying antirheumatic drugs. Seminars in Arthritis and Rheumatism 2020; 50 (4): 564-570. doi: 10.1016/j.semarthrit.2020.05.001
15. Quartuccio L, Valent F, Pasut E, Tascini C, De Vita S. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine 2020; 87 (5): 439-443. doi: 10.1016/j.jbspin.2020.05.003
16. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395 (10223): 473-475. doi: 10.1016/S0140- 6736(20)30317-2
17. Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. Journal of Clinical Virology 2004; 31 (4): 304-309. doi: 10.1016/j. jcv.2004.07.006
18. Boekel L, Kummer LY, van Dam KPJ, Hooijberg F, van Kempen Z et al. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. Lancet Rheumatology 2021; 3 (8): e542-e545. doi: 10.1016/S2665-9913(21)00181-8